This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
However, information on its efficacy and safety in patients with heartfailure remains limited. Case presentation A 43-year-old man with a body mass index of 41 kg/m 2 was admitted to our hospital for acute heartfailure due to dilated cardiomyopathy. No adverse events were observed during B-SES.
Despite being a hearttransplantation candidate, she declined revascularization and sought alternative treatments for angina, dyspnea, and daily activity limitations. Not only did EECP improve the patient's angina and functional status, but it also enhanced her cardiacfunction.
The DRAIN-HF study will evaluate the Aortix percutaneous mechanical circulatory support (pMCS) technology in patients with acute decompensated heartfailure (ADHF) who are unresponsive to standard medical therapy. The Aortix pump demonstrated promising results to help off-load fluid and improve kidney function.
Heart attacks typically kill millions of cardiac muscle cells, leaving the heart in a weakened state. Since mammals cannot regenerate cardiac muscle cells on their own, hearttransplants are currently the only clinically viable option for patients suffering (or likely to suffer) heartfailure.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
124 
Let's personalize your content